The Lipidomic Signature of Glioblastoma: A Promising Frontier in Cancer Research

3Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

Glioblastoma is the most aggressive primary brain malignancy in adults, and has a survival duration of approximately 15 months. First line treatment involves surgical resection, chemotherapy, and radiation, but despite the multi-pronged approach and advances in cancer research, glioblastoma remains devastating with a high mortality rate. Lipidomics is an emerging discipline that studies lipid pathways and characteristics, and is a promising field to understand biochemical mechanisms. In glioblastoma, disrupted lipid homeostasis has been reported in the literature. A thorough understanding of serum lipidomics may offer ways to better understand glioblastoma biomarkers, prognosis, and treatment options. Here, we review the literature, offering future directions for lipidomics research in glioblastomas.

Author supplied keywords

Cite

CITATION STYLE

APA

Yu, N., & Aboud, O. (2024, March 1). The Lipidomic Signature of Glioblastoma: A Promising Frontier in Cancer Research. Cancers. Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/cancers16061089

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free